Emergent Biosolutions Inc. (EBS) said the U.S. Food and Drug Administration has granted orphan-drug status to its BioThrax treatment for patients suspected or confirmed to have been exposed to anthrax.
Click here for the article.
Emergent Biosolutions Inc. (EBS) said the U.S. Food and Drug Administration has granted orphan-drug status to its BioThrax treatment for patients suspected or confirmed to have been exposed to anthrax.
Click here for the article.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.